Pharma point multiple sclerosis india drug forecast and market analysis to 2022 - Reports Corner

  • 161 views
Uploaded on

Global Data has released its new Country report, "PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological …

Global Data has released its new Country report, "PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system.

https://www.reportscorner.com/reports/15505/PharmaPoint:-Multiple-Sclerosis---India-Drug-Forecast-and-Market-Analysis-to-2022/

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
161
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
4
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. RCReports CornerPharmaPoint: Multiple Sclerosis - India DrugForecast and Market Analysis to 2022
  • 2. DescriptionDescriptionReports Cornerwww.reportscorner.comGlobalData has released its new Country report, "PharmaPoint:Multiple Sclerosis - India Drug Forecast and Market Analysis to2022". Multiple sclerosis (MS) is a chronic, inflammatoryneurological disorder characterized pathologically bydemyelination, axonal transection and neurodegeneration withinthe central nervous system.
  • 3. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comPharmaPoint: Multiple Sclerosis - India Drug Forecast and MarketAnalysis to 2022SummaryGlobalData has released its new Country report, "PharmaPoint:Multiple Sclerosis - India Drug Forecast and Market Analysis to2022". Multiple sclerosis (MS) is a chronic, inflammatoryneurological disorder characterized pathologically bydemyelination, axonal transection and neurodegeneration withinthe central nervous system. With curative therapy still elusive,current disease management is dependent on life-longpharmacotherapy with disease-modifying therapies (DMT). Thedominance of first-line injectable DMTs, including the interferonbeta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b),Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), andTeva’s Copaxone (glatiramer acetate), has been a salient featureof the MS therapeutics market.
  • 4. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comHowever, the competitive landscape is undergoing significantchange with the emergence of oral therapies, several pipelineproducts with notable efficacies, and loominggenerics/biosimilars following the patent expiries of key brandedproducts during the forecast period. In addition, the entry of newcompanies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the establishedplayers in the MS marketplace.MS has a low prevalence in India, which could be due to geneticsor environmental factors. However, many physicians surveyed forthis report mostly use the Poser criteria to diagnose patients,given the lack of current accessibility to sensitive diagnostictools, such as MRI. Therefore, it is possible that the current rate ofMS in India is grossly underestimated, meaning a large proportionof undiagnosed MS patients are not captured and providedadequate treatment.
  • 5. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe major drivers of growth in this market will be the launch oforal DMTs and an increase in availability of advanced diagnostictools, which will likely lead to increased diagnosis and treatmentrates over the forecast period.Note: This is upcoming report and will be delivered within 24 hrsof the purchase (excluding weekends).Scope- Overview of the Multiple Sclerosis including epidemiology,etiology, symptoms, diagnosis, pathology and treatmentguidelines as well as an overview on the competitive landscape.- Detailed information on the key drugs in India including productdescription, safety and efficacy profiles as well as a SWOTanalysis.
  • 6. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com- Sales forecast for the top drugs in India from 2012-2022.- Analysis of the impact of key events as well the drivers andrestraints affecting India Multiple Sclerosis market.Reasons to buy- Understand and capitalize by identifying products that are mostlikely to ensure a robust return- Stay ahead of the competition by understanding the changingcompetitive landscape for Multiple Sclerosis- Effectively plan your M&A and partnership strategies byidentifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of drug performance- Obtain sales forecast for drugs from 2012-2022 in India
  • 7. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com1 Table of Contents 41.1 List of Tables 81.2 List of Figures 102 Introduction 112.1 Catalyst 112.2 Related Reports 122.3 Upcoming Related Reports 133 Disease Overview 143.1 Etiology and Pathophysiology 143.1.1 Etiology 143.1.2 Pathophysiology 153.1.3 Classification of Multiple Sclerosis 163.2 Symptoms 183.2.1 Prognosis 193.2.2 Quality of Life 20
  • 8. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com4 Disease Management 214.1 Diagnosis 214.2 Treatment Overview 244.2.1 Management of Acute Relapse 254.2.2 Treatment with Disease-Modifying Therapies 254.2.3 Symptomatic Therapies 284.3 India 294.3.1 Diagnosis 294.3.2 Clinical Practice 295 Competitive Assessment 315.1 Overview 315.2 Strategic Competitor Assessment 325.3 Product Profiles – Major Brands 335.3.1 Betaseron/Betaferon (interferon beta-1b) 335.3.2 Avonex
  • 9. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com5.3.2 Avonex (interferon beta-1a) 375.3.3 Rebif (interferon beta-1a) 425.3.4 Copaxone (glatiramer acetate; copolymer-1) 465.3.5 Tysabri (natalizumab) 505.3.6 Gilenya/Imusera (fingolimod; FTY720) 545.3.7 Aubagio (teriflunomide) 595.3.8 Other Disease–Modifying Therapies 636 Opportunity and Unmet Need 646.1 Overview 646.2 Unmet Needs 656.2.1 Currently Available MS Drugs Only Provide Partial Benefits 656.2.2 The High Cost of MS Drugs Could Continue to Price out Patients 666.2.3 Effective Treatments for Progressive MS Are Still Elusive 676.2.4 Inconvenient Route of Administration and Frequent Dosing Limits Compliance 686.2.5 The Lack of Predictive Biomarkers Delays MS Diagnosis 69
  • 10. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com6.3 Unmet Needs Gap Analysis 696.4 Opportunities 706.4.1 Treatments for Progressive MS 706.4.2 Targeting Patients with Clinically Isolated Syndrome 717 Pipeline Assessment 727.1 Overview 727.2 Promising Drugs in Clinical Development 737.2.1 BG-12 (dimethyl fumarate; BG00012) 767.2.2 Lemtrada (alemtuzumab) 807.2.3 Laquinimod (ABR-215062) 857.2.4 Daclizumab High-Yield Process (HYP) 907.2.5 Ocrelizumab (RG1594) 947.2.6 Siponimod (BAF-312) 987.2.7 NU-100 (interferon beta-1b) 1027.2.8 Masitinib (AB-1010) 105
  • 11. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com7.2.9 Tcelna (imilecleucel-T) 1088 Market Outlook 1138.1 India 1138.1.1 Forecast 1138.1.2 Key Events 1158.1.3 Drivers and Barriers 1169 Appendix 1189.1 Bibliography 1189.2 Abbreviations 1299.3 Methodology 1339.4 Forecasting Methodology 1339.4.1 Diagnosed MS patients 1339.4.2 Percent Drug-Treated Patients 1339.4.3 Drugs Included in Each Therapeutic Class 1349.4.4 General Pricing Assumptions 134
  • 12. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com9.4.5 Individual Drug Assumptions 1359.4.6 Generic Erosion 1399.4.7 Pricing of Pipeline agents 1399.5 Physicians and Specialists Included in This Report 1409.6 Primary Research – Prescriber Survey 1419.7 About the Authors 1429.7.1 Analysts 1429.7.2 Global Head of Healthcare 1439.8 About GlobalData 1449.9 Contact Us 1449.10 Disclaimer 144
  • 13. For more informationFor more informationReports Cornerwww.reportscorner.comFor more information please visit our websitehttps://www.reportscorner.com/reports/15505/PharmaPoint:-Multiple-Sclerosis---India-Drug-Forecast-and-Market-Analysis-to-2022/
  • 14. Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: contact@reportscorner.com